Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label phase II trial. Eligible patients must have histological or
clinical diagnosis of Hepatocellular Carcinoma (HCC), advanced tumors that are not amenable
to loco-regional therapy, documented progression with or intolerance to sorafenib-based
treatment or other anti-angiogenic therapy as first-line therapy for advanced HCC.